WO2021060439A1 - ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール - Google Patents

ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール Download PDF

Info

Publication number
WO2021060439A1
WO2021060439A1 PCT/JP2020/036195 JP2020036195W WO2021060439A1 WO 2021060439 A1 WO2021060439 A1 WO 2021060439A1 JP 2020036195 W JP2020036195 W JP 2020036195W WO 2021060439 A1 WO2021060439 A1 WO 2021060439A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
bond
drug
antibody
formula
Prior art date
Application number
PCT/JP2020/036195
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
佑紀 松野
宏樹 吉岡
輝 鈴木
Original Assignee
日油株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日油株式会社 filed Critical 日油株式会社
Priority to CN202080067753.8A priority Critical patent/CN114450324B/zh
Priority to JP2021549023A priority patent/JPWO2021060439A1/ja
Priority to EP20868583.4A priority patent/EP4036149A4/en
Priority to US17/762,719 priority patent/US20220362397A1/en
Priority to KR1020227013431A priority patent/KR20220069989A/ko
Priority to CA3156027A priority patent/CA3156027A1/en
Publication of WO2021060439A1 publication Critical patent/WO2021060439A1/ja

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen

Definitions

  • the present invention relates to a peptide linker and a heterobifunctional monodisperse polyethylene glycol having two different chemically reactive functional groups. More specifically, it is used to modify biofunctional molecules such as physiologically active proteins, peptides, antibodies, nucleic acids and small molecule drugs, drug carriers in drug delivery systems, or diagnostic materials and medical devices, especially modifications to antibody drugs. With respect to peptide linkers, and heterobifunctional monodisperse polyethylene glycols having two different chemically reactive functional groups.
  • An antibody-drug conjugate is an antibody drug that binds a drug to an antibody and actively transports the drug to the diseased site by utilizing the antigen specificity of the antibody. In recent years, it is one of the fastest growing technologies in the field of cancer treatment.
  • the ADC consists of an antibody, a drug, and parts of a linker that binds the antibody to the drug.
  • Many of the drugs used for ADC are hydrophobic, and when a plurality of these hydrophobic drugs are bound to an antibody to prepare an ADC, there are problems such as agglutination due to the hydrophobicity of the drug and a decrease in blood stability of the antibody. It becomes. Therefore, the number of drugs that can be loaded per antibody is limited, and as a result, the efficacy of the ADC may not be sufficiently obtained.
  • hydrophilic linkers Polyethylene glycol, hydrophilic peptides, sugar chains, etc. are used as hydrophilic linkers.
  • polyethylene glycol has low antigenicity and high biocompatibility, and therefore, several of them are currently in clinical trials and preclinical trials. It is used in ADC.
  • compounds containing 90% or more of components having a specific ethylene glycol chain length are used for the purpose of ensuring the uniformity of ADC and facilitating purification, analysis and drug approval application.
  • Such compounds are referred to as monodisperse polyethylene glycol.
  • ADC linker When monodisperse polyethylene glycol is used as an ADC linker, it is necessary to separately bond the antibody and the drug, so heterobifunctional monodisperse polyethylene glycol having two different chemically reactive functional groups is used.
  • ADCs are prepared using compounds having different chemically reactive functional groups at both ends of a monodisperse polyethylene glycol chain.
  • ADCs have been reported in which monodisperse polyethylene glycol is introduced as a side chain into a branched linker that connects an antibody and a drug, instead of using monodisperse polyethylene glycol as a linker main chain that connects an antibody and a drug.
  • Non-Patent Document 1 the pharmacokinetics of an ADC using monodisperse polyethylene glycol as the main chain of the linker connecting the antibody and the drug, and the pharmacokinetics of the ADC using monodisperse polyethylene glycol as the side chain of the branched linker connecting the antibody and the drug.
  • the therapeutic effects are compared, and it has been reported that the latter has a higher masking effect on the hydrophobicity of the drug and exhibits excellent pharmacokinetics and therapeutic effect.
  • Patent Document 1 and Patent Document 2 disclose various types of ADCs having monodisperse polyethylene glycol as a side chain of a branched linker, and intermediates for preparing them.
  • Patent Document 3 two monodisperse polyethylene glycols are bonded to a quaternary carbon atom in a quaternary skeleton, and heterobifunctional monodisperse polyethylene glycol having two kinds of functional groups at two ends of the branches. And ADCs using it are disclosed.
  • Patent Document 1 and Patent Document 2 also disclose an ADC having two or more monodisperse polyethylene glycols in the side chain of the branched linker.
  • Non-Patent Document 1 and Patent Document 3 disclose a branched monodisperse polyethylene glycol having a monodisperse polyethylene glycol in the side chain of the branched linker, and an ADC using this for binding an antibody and a drug.
  • the antibody is decomposed by the intracellular enzyme, but the monodisperse polyethylene glycol is bound to the drug, which may reduce the activity of the drug. , Not preferable.
  • the present invention relates to an antibody-drug conjugate in which an antibody and a drug are linked by a peptide linker and a linker having a monodisperse polyethylene glycol side chain. That is, the subject of the present invention is a heterodrug having two adjacent monodisperse polyethylene glycol side chains in which the peptide linker is decomposed by an intracellular enzyme to release the drug slowly and effectively shield the hydrophobicity of the drug. It is to provide a functional monodisperse polyethylene glycol and an antibody-drug conjugate using which an antibody and a drug are bound.
  • the present inventor has a peptide linker that is degraded by an intracellular enzyme, and two monodisperse polyethylene glycol side chains are closely bound to each other.
  • Heterobifunctional monodisperse polyethylene glycol which is a functional compound, and an antibody-drug conjugate in which an antibody and a drug are bound using the polyethylene glycol were developed.
  • heterobifunctional monodisperse polyethylene glycol of the present invention since two monodisperse polyethylene glycol side chains are bonded to the quaternary carbon atom of the branched portion by a stable ether bond, the heterobifunctional monodisperse is said. In the chemical conversion process of the structure of dispersed polyethylene glycol, it has a feature that it is difficult to decompose into single-stranded monodisperse polyethylene glycol.
  • the heterobifunctional monodisperse polyethylene glycol of the present invention has a peptide linker that is decomposed by an intracellular enzyme, the drug can be effectively sustained in the cell, and the drug can be released intracellularly. It has the characteristic that it does not affect the activity of the drug.
  • X 1 and Y 1 are atomic groups containing at least a functional group that reacts with a functional group existing in a biofunctional molecule to form a covalent bond, and the functional group contained in the atomic group X 1 and the atomic group Y 1 are Different from the functional groups containing;
  • R 1 is a hydrocarbon group or hydrogen atom with 1 to 7 carbon atoms;
  • n is an integer from 3 to 72;
  • a 1 is -L 1- (CH 2 ) m1 -L 2- , -L 1- (CH 2 ) m1 -L 2- (CH 2 ) m2- , amide bond, urethane bond, secondary amino group or single bond ,
  • m1 and m2 independently represent integers from 1 to 5;
  • B 1 represents -CH 2 -L 3 -, - CH 2 -L 3 - (CH 2) m3 -L 4 - or -CH 2 -L 3 - (CH 2 ) m3 -L 4
  • W is an oligopeptide of 2 to 4 residues consisting of at least one of the hydrophobic neutral amino acids of phenylalanine, leucine, valine, and isoleucine, and the other amino acids are neutral amino acids excluding cysteine.
  • W contains at least one of the hydrophobic neutral amino acids of phenylalanine, leucine, valine and isoleucine, and the other amino acids have at least one of alanine, glycine, citrulin, proline, serine and asparagine 2
  • X 1 and Y 1 in Eq. (1) are independently Eqs. (a), Eq. (B1), Eqs. (b2), Eqs. (c), Eqs. (d1), Eqs. (d2), Eqs. (e), equation (f), equation (g), equation (h), equation (i), equation (j), equation (k), equation (l), equation (m), equation (n) and equation
  • the heterobifunctional monodisperse polyethylene glycol according to any one of [1] to [5], which is selected from the group consisting of (o).
  • R 2 is a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms
  • R 3 is selected from a chlorine atom, a bromine atom and an iodine atom. It is a halogen atom
  • R 4 is a hydrogen atom or a hydrocarbon group with 1-5 carbon atoms.
  • X 2 and Y 2 is an antibody and the other is a drug;
  • R 1 is a hydrocarbon group or hydrogen atom with 1 to 7 carbon atoms;
  • n is an integer from 3 to 72;
  • a 2 is -L 1 - (CH 2) m1 -L 7 -, - L 1 - (CH 2) m1 -L 8 -, - L 1 - (CH 2) m1 -L 2 - (CH 2) m2 - L 8 - or -L 8 - represents, m1 and m2 each independently represents an integer of 1 to 5;
  • B 2 is -CH 2 -L 9 -, - CH 2 -L 9 - (CH 2) m3 -L 10 -, - CH 2 -L 9 - (CH 2) m3 -L 10 - (CH 2) m4 - L 11 -, - CH 2 -L 12 -, - CH 2 -L 9 - (CH 2) m3
  • W is an oligopeptide of 2 to 4 residues consisting of at least one of the hydrophobic neutral amino acids of phenylalanine, leucine, valine, and isoleucine, and the other amino acids are neutral amino acids excluding cysteine.
  • the antibody-drug complex according to [7].
  • W contains at least one of the hydrophobic neutral amino acids of phenylalanine, leucine, valine, and isoleucine, and the other amino acids have at least one of alanine, glycine, citrulin, proline, serine, and asparagine 2
  • the heterobifunctional monodisperse polyethylene glycol since two monodisperse polyethylene glycol side chains are bonded to the quaternary carbon atom of the branched portion by a stable ether bond, the heterobifunctional monodisperse polyethylene glycol has a single chain in the chemical conversion process. Hard to decompose into monodisperse polyethylene glycol. Therefore, by binding the antibody to the drug using the heterobifunctional monodisperse polyethylene glycol, an antibody-drug conjugate with high homogeneity can be obtained.
  • heterobifunctional monodisperse polyethylene glycol has two monodisperse polyethylene glycol side chains bonded in close proximity to each other, a large shielding effect of the hydrophobic drug is obtained when an antibody-drug complex is prepared. It is possible to suppress the occurrence of aggregation due to the hydrophobicity of the drug and the decrease in the blood stability of the antibody.
  • heterobifunctional monodisperse polyethylene glycol contains a peptide linker that is degraded by an intracellular enzyme, the linker site is cleaved from the drug in the cell, and the drug is effectively sustained-release in the cell. Can be done.
  • Example 37 of the compound of the formula (20) of Example 10 The HPLC measurement results before and after the degradability test in Example 37 of the compound of the formula (20) of Example 10 are shown.
  • the mass chromatogram of the decomposition product derived from the compound of the formula (20) after the degradability test of Example 37 is shown.
  • the HPLC measurement results before and after the degradability test in Example 37 of the compound of the formula (44) of Comparative Example 2 are shown.
  • the HPLC measurement results before and after the degradability test in Example 38 of the compound of the formula (21) of Example 11 are shown.
  • the mass chromatogram of the decomposition product derived from the compound of the formula (21) after the degradability test of Example 38 is shown.
  • the HPLC measurement results before and after the degradability test in Example 38 of the compound of the formula (26) of Example 16 are shown.
  • the HPLC measurement results before and after the degradability test in Example 39 of the compound of the formula (40) of Example 30 are shown.
  • the mass chromatogram of the decomposition product derived from the compound of the formula (40) after the degradability test of Example 39 is shown.
  • the HPLC measurement results before and after the degradability test in Example 39 of the compound of the formula (46) of Comparative Example 4 are shown.
  • the mass chromatogram of the decomposition product derived from the compound of the formula (42) after the degradability test of Example 40 is shown.
  • the graph which plotted the cell viability per the sample concentration in the cytotoxicity test of Example 41 using the drug-linker compound of the formula (40) and the formula (46) is shown.
  • the graph which plotted the cell viability per the sample concentration in the cytotoxicity test of Example 42 using the drug-linker compound of the formula (42) and the formula (46) is shown.
  • heterofunctional means having two different chemically reactive functional groups
  • monodisperse polyethylene glycol means 90% of components having a specific ethylene glycol chain length.
  • linker is a chemical site that covalently binds an antibody to a drug or contains a carbon chain.
  • the heterobifunctional monodisperse polyethylene glycol of the present invention is represented by the formula (1).
  • R 1 in the formula (1) of the present invention is a hydrocarbon group or a hydrogen atom having 1 to 7 carbon atoms, and specific hydrocarbon groups include a methyl group, an ethyl group, a propyl group, an isopropyl group and a t-butyl group. , Phenyl group, benzyl group and the like.
  • a preferred embodiment of R 1 is a methyl group or a hydrogen atom, more preferably a methyl group.
  • N in the formula (1) of the present invention is an integer of 3 to 72 representing the number of repeating units of monodisperse polyethylene glycol, preferably an integer of 4 to 48, and more preferably an integer of 6 to 36. Particularly preferably, it is an integer of 8 to 24.
  • the atomic groups X 1 and Y 1 of the formula (1) are different from each other, and the biofunctional molecule (physiologically active protein, peptide, antibody, nucleic acid) to be modified by the heterobifunctional monodisperse polyethylene glycol is used. It is not particularly limited as long as it is an atomic group containing at least a functional group that reacts with a functional group existing in (such as a small molecule drug) to form a covalent bond.
  • the functional groups contained in X 1 and Y 1 are independently functional groups (amino group, thiol group, aldehyde group, carboxy group, etc.) existing in natural biofunctional molecules represented by proteins and the above. It is preferable that the functional group can react with a functional group (maleimide group, ketone group, azido group, alkynyl group, etc.) that can be artificially introduced into a biofunctional molecule under mild reaction conditions and with high reaction efficiency.
  • active ester group active carbonate group, aldehyde group, isocyanate group, isothiocyanate group, epoxy group, maleimide group, vinylsulfone group, acrylic group, sulfonyloxy group, carboxy group, thiol group, 2-pyridyl.
  • a dithio group, an ⁇ -haloacetyl group, a hydroxy group, an alkynyl group, an allyl group, a vinyl group, an amino group, an oxyamino group, a hydrazide group, an azide group, and a dibenzocyclooctine (DBCO) group are preferable, and further considering the reaction efficiency.
  • Active ester group, active carbonate group, maleimide group, ⁇ -haloacetyl group, alkynyl group, azido group and dibenzocyclooctine (DBCO) group are preferable, and active ester group, active carbonate group and maleimide group are more preferable.
  • the functional groups contained in X 1 and Y 1 are independently active ester groups and active carbonates when the functional group present in the biofunctional molecule to be modified is an amino group.
  • an active ester group In the case of a group, an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a maleimide group, a vinylsulfone group, an acrylic group, a sulfonyloxy group, a carboxy group, a thiol group, 2- If the functional group present in the biofunctional molecule to be modified is an aldehyde group or a carboxy group, which is a pyridyldithio group, an ⁇ -haloacetyl group, an alkynyl group, an allyl group or a vinyl group, a thiol group or a hydroxy group.
  • the functional group present in the biofunctional molecule to be modified is an alkynyl group, which is a group, amino group, oxyamino group or hydrazide group, it is a thiol group or azide group and is subject to modification.
  • the functional group present in the biofunctional molecule is an azide group, it is an alkynyl group and a dibenzocyclooctine group
  • the functional group present in the biofunctional molecule to be modified is an alkyl halide group or an alkylsulfone.
  • it is an acid ester or an arylsulfonic acid ester, it is a thiol group, a hydroxy group or an amino group.
  • Leaving groups represented by E include succinimidyloxy group, phthalimidyloxy group, 4-nitrophenoxy group, 1-imidazolyl group, pentafluorophenoxy group, benzotriazole-1-yloxy group and 7-. Examples thereof include azabenzotriazole-1-yloxy group, and succinimidyloxy group and 4-nitrophenoxy group are preferable.
  • X 1 and Y 1 are shown independently in groups (I), group (II), group (III), group (IV), group (V) or group (VI), respectively.
  • Group (I) Functional groups capable of reacting with amino groups of biofunctional molecules to form covalent bonds (a), (b1), (b2), (c), (d1), ( d2), (e) and (f)
  • Group (II) Functional groups capable of reacting with the thiol group of a biofunctional molecule to form a covalent bond The following (a), (b1), (b2), (c), (d1), ( d2), (e), (f), (g), (h) and (l)
  • Group (III) Functional groups capable of reacting with an aldehyde group or a carboxy group of a biofunctional molecule to form a covalent bond The following (g), (i), (j), (k) and (o) )
  • Group (IV) Functional groups capable of reacting with the alkyn
  • R 2 and R 4 are hydrogen atoms or hydrocarbon groups having 1 to 5 carbon atoms, and specific hydrocarbon groups include methyl group, ethyl group, propyl group, isopropyl group, butyl group and t-butyl. Examples include groups and pentyl groups.
  • R 3 is a halogen atom selected from chlorine, bromine and iodine atoms.
  • the functional group contained in the atomic groups X 1 and Y 1 of the formula (1) when the functional group contained in X 1 is an active ester group or an active carbonate group, the functional group contained in Y 1 is maleimide.
  • the functional group contained in X 1 is an aldehyde group
  • the functional group contained in Y 1 is a maleimide group or vinyl.
  • the functional group contained in is an alkynyl group, an azide group, a thiol group, a hydroxy group or a carboxy group, and when the functional group contained in X 1 is a thiol group, a 2-pyridyldithio group or a hydroxy group, Y 1 is an amino group.
  • the functional group contained in Y 1 is a group selected from an active ester group, an active carbonate group, an alkynyl group and an azido group, and the functional group contained in X 1.
  • the functional group contained in Y 1 is a group selected from a maleimide group, an ⁇ -haloacetyl group, an active ester group, an active carbonate group, an amino group, an oxyamino group and a hydroxy group.
  • the functional group contained in X 1 is an amino group or an oxyamino group
  • the functional group contained in Y 1 is an alkynyl group, an azido group, a hydroxy group or a thiol group
  • the functional group contained in X 1 is thiol.
  • the functional group contained in Y 1 is a group selected from an amino group, an oxyamino group and an azide group.
  • W in formula (1) is a degradable linker that is specifically cleaved by intracellular lysosomal enzymes.
  • Such linkers are, for example, peptide-based structures.
  • Degradable peptide linkers generally have good blood stability because lysosomal enzymes are activated only in the low pH environment of intracellular lysosomes. The release of the drug from the antibody is specifically caused by the action of lysosomal enzymes such as cathepsin and plasmin. These enzymes may be present at high levels in certain tumor tissues.
  • the linker can be cleaved by a lysosomal enzyme, examples of this lysosomal enzyme include cathepsin B and the like.
  • W in the formula (1) is not particularly limited as long as it is an oligopeptide having 2 to 4 residues that is stable in the blood in vivo and decomposed by an intracellular enzyme, but it is an antibody-drug complex.
  • an oligopeptide containing a more hydrophilic amino acid In order to maximize the hydrophobicity of the drug during preparation and suppress the aggregation caused by the hydrophobicity of the drug, it is preferable to use an oligopeptide containing a more hydrophilic amino acid.
  • dipeptides are more preferred than longer peptides because longer peptides are hydrophobic.
  • W in formula (1) is a 2-4 residue having at least one hydrophobic neutral amino acid having a hydropathy index of 2.5 or more, specifically phenylalanine, leucine, valine, or isoleucine.
  • oligopeptide of It is preferably an oligopeptide of, and more preferably an oligopeptide of 2 to 4 residues having valine or phenylalanine.
  • the hydropathy index which is created by Kyte and Doolittle and quantitatively indicates the hydrophobicity of amino acids, indicates that the larger the value, the more hydrophobic the amino acid (Kyte J & Doolittle RF, 1982, J Mol. Biol, 157: 105-132.).
  • W in the formula (1) is a neutral amino acid having a LogP value calculated by XLogP3 less than -2.5, specifically, alanine, glycine, citrulin, proline, It is preferably an oligopeptide of 2 to 4 residues having at least one of serine and asparagine, and more preferably an oligopeptide of 2 to 4 residues having at least one of alanine, glycine and citrulin.
  • LogP is defined as the logarithm of the partition coefficient of octanol / water, and is a value that is an index of hydrophobicity. The smaller the value, the more hydrophilic the value.
  • XlogP3 is a method for calculating the LogP value created by Cheng et al. (Cheng, T. et al. J Chem Inf Model. 2007, 47: 2140-2148).
  • W in the formula (1) is preferably an oligopeptide of 2 to 4 residues having glycine as a C-terminal amino acid.
  • a condensing agent or the like When reacting the C-terminal carboxyl group, it is basically necessary to activate the C-terminal carboxyl group with a condensing agent or the like. It is known that in this activation step, amino acids other than glycine are prone to epimerization and the stereoisomers are replicated.
  • achiral glycine as the amino acid at the C-terminal of the oricopeptide, it is possible to obtain a high-purity target product without by-production of steric isomers.
  • W in the formula (1) is an oligopeptide of 2 to 4 residues composed of amino acids having an amino group or a carboxyl group in the side chain, specifically, amino acids not containing lysine, aspartic acid, and glutamic acid. Is preferable.
  • the N-terminal amino group or C-terminal carboxyl group of the oligopeptide is used in the reaction. are doing.
  • the polyethylene glycol portion is not only the target N-terminal amino group or C-terminal carboxyl group, but also the side chain amino group or carboxyl group. Also introduces impurities. Since it is difficult to remove this impurity by a purification process such as ordinary extraction or crystallization, in order to obtain the desired product with high purity, an oligopeptide consisting of an amino acid having no amino group or carboxyl group in the side chain should be used. Is desirable.
  • the amino acid used here is an ⁇ -amino acid and is basically L-type.
  • W in the formula (1) is an oligopeptide composed of amino acids containing no cysteine. Is preferable.
  • W in the formula (1) should be an oligopeptide having 2 to 4 residues consisting of neutral amino acids excluding cysteine, which is stable in the blood in the living body and has the ability to be decomposed by intracellular enzymes.
  • valine-citrulin valine-alanine, phenylalanine-glycine, etc., preferably glycine-phenylalanine-leucine-glycine, glycine-glycine-phenylalanine-glycine, valine-citrulin-glycine, valine-alanine-glycine, valine -Citrulin, valine-alanine, phenylalanine-glycine, more preferably valine-citrulin, valine-alanine, or phenylalanine-glycine, and even more preferably valine-citrulin.
  • Z in formula (1) is an autolytic spacer that further separates the drug from the site where the peptide linker represented by W is enzymatically cleaved.
  • the peptide linker moiety remains in the drug when the peptide linker is cleaved, which may lead to a decrease in the activity of the drug.
  • the use of autolytic spacers allows the release of peptide linker-free drugs during hydrolysis of the amide bond.
  • One of the self-degrading spacers is a bifunctional para-aminobenzyl alcohol group, which is linked to the peptide via an amino group to form an amide bond, while drugs with an amino group or hydroxyl group , Can be attached to the benzyl alcohol group of the linker via a carbamate or carbonate bond (given para-aminobenzyl carbamate or para-aminobenzyl carbonate).
  • the resulting prodrug is activated upon cleavage of the peptide-linker amide bond, resulting in a 1,6-elimination reaction, releasing the peptide linker-free drug, carbon dioxide and the rest of the linker group.
  • this group causes an elimination reaction only when the amide bond on the C-terminal side of the peptide linker is cleaved and releases a drug that does not contain the peptide linker. Therefore, the C-terminal of the peptide linker is on the monodisperse polyethylene glycol side. It is not always necessary if it is present and not on the drug side.
  • the scheme below illustrates fragmentation of para-amide benzyl carbamate or para-amide benzyl carbonate, and release of the drug:
  • XD represents a drug that does not contain a peptide linker.
  • B in equation (1) is 0 or 1.
  • the autolytic spacer represented by Z in the formula (1) is not included, and when b is 1, the autolytic spacer represented by Z in the formula (1) is included.
  • a 1 in the formula (1) of the present invention is a divalent spacer between the quaternary carbon atom of the branched portion and W or X 1
  • B 1 in the formula (1) is the quaternary carbon of the branched portion. It is a divalent spacer between an atom and W or Y 1
  • C 1 in equation (1) is a divalent spacer between Z and X 1 or Y 1 , each composed of a covalent bond. ..
  • a 1 is -L 1- (CH 2 ) m1 -L 2- , -L 1- (CH 2 ) m1 -L 2- (CH 2 ) m2- , amide bond, urethane bond, grade 2 Represents an amino group or single bond, preferably -L 1- (CH 2 ) m1- L 2- , -L 1- (CH 2 ) m1- L 2- (CH 2 ) m2- , amide bond, secondary amino It is a group, more preferably -L 1- (CH 2 ) m1- L 2- (CH 2 ) m2- , amide bond, secondary amino group.
  • m1 and m2 are independently integers from 1 to 5.
  • B 1 is -CH 2 -L 3 -, - CH 2 -L 3 - (CH 2) m3 -L 4 - or -CH 2 -L 3 - (CH 2 ) m3 -L 4 - (CH 2) m4 - represents, preferably -CH 2 -L 3 - is - or -CH 2 -L 3 - (CH 2 ) m3 -L 4.
  • m3 and m4 are independently integers from 1 to 5.
  • C 1 is -L 5 - (CH 2) m5 -, - L 5 - (CH 2) m5 -L 6 - (CH 2) m6 -, an amide bond or a single bond, is preferably a single bond .
  • m5 and m6 are independently integers from 1 to 5.
  • L 1 to L 6 in the above formula are independently divalent spacers, and specifically, they are an ether bond, a urethane bond, an amide bond, a secondary amino group, a carbonyl group or a single bond.
  • L 1 and L 2 are preferably urethane bond, amide bond or secondary amino group independently
  • L 3 is preferably ether bond, urethane bond or single bond
  • L 4 is amide bond, urethane bond or secondary.
  • An amino group, a carbonyl group or a single bond is preferable
  • L 5 is preferably a urethane bond
  • L 6 is preferably an amide bond, a urethane bond or a secondary amino group.
  • the heterobifunctional monodisperse polyethylene glycol of the formula (1) in a preferred embodiment of the present invention can be produced, for example, by the following steps.
  • the compound represented by the above formula (3) is subjected to a nucleophilic substitution reaction with an alkyl or aryl sulfonic acid ester of monomethyl monodisperse polyethylene glycol or a halide of monomethyl monodisperse polyethylene glycol in the presence of a strong base in an anhydrous solvent.
  • the compound represented by the following formula (4) is obtained.
  • the "protecting group” is a component that prevents or prevents the reaction of a specific functional group in the molecule under certain reaction conditions.
  • Protecting groups vary depending on the type of functional group protected, the conditions used and the presence of other functional or protecting groups in the molecule. Specific examples of protecting groups can be found in many common books, such as "Wuts, P. G. M .; Greene, T. W. Protective Groups in Organic Synthesis, 4th ed .; Wiley. -Interscience: New York, 2007 ”.
  • the functional group protected by the protecting group can be regenerated by deprotecting, that is, chemically reacting with the reaction conditions suitable for each protecting group. Typical deprotection conditions for protecting groups are described in the aforementioned literature.
  • a preferred combination of the protected functional group and the protecting group is, for example, an acyl-based protecting group and a carbamate-based protecting group when the protected functional group is an amino group, specifically a trifluoroacetyl group, 9- Examples include a fluorenylmethyloxycarbonyl group, a t-butyloxycarbonyl group and a 2- (trimethylsilyl) ethyloxycarbonyl group.
  • the functional group to be protected is a hydroxy group
  • examples thereof include a silyl-based protecting group and an acyl-based protecting group, specifically, a t-butyldiphenylsilyl group, a t-butyldimethylsilyl group, and a triisopropylsilyl group. , Acetyl group and pivaloyl group and the like.
  • the functional group to be protected is a carboxy group
  • an alkyl ester-based protecting group and a silyl ester-based protecting group can be mentioned, and specific examples thereof include a methyl group, a 9-fluorenylmethyl group and a t-butyldimethylsilyl group.
  • the functional group to be protected is a sulfanyl group, for example, a thioether-based protecting group, a thiocarbonate-based protecting group and a disulfide-based protecting group can be mentioned, and specifically, S-2,4-dinitrophenyl group and S-9- Examples include a fluorenylmethyloxycarbonyl group and a St-butyl disulfide group.
  • a bifunctional protecting group capable of simultaneously protecting two functional groups of the same type or different types may be used.
  • a preferred combination of the protected functional group and the protective group is, for example, a cyclic acetal-based protective group and a cyclic silyl-based protective group when the protected functional group is two hydroxy groups, specifically 2,2. -Dimethyl-1,3-dioxolan group, 2,2-dimethyl-1,3-dioxane group, 2-phenyl-1,3-dioxolan group, 2-phenyl-1,3-dioxane group and di-t-butyl Examples include a silylene group.
  • the functional groups to be protected are an amino group and a hydroxy group, for example, an oxazoline-based protecting group can be mentioned, and specifically, a 2-phenyloxazoline group and the like can be mentioned.
  • Typical deprotection conditions for protecting groups are described in the above-mentioned literature, and reaction conditions suitable for each protecting group can be selected. However, if the functional group contained in the structure is a functional group that does not inhibit the chemical reaction of other functional groups even if it is not protected by the protecting group, it is not necessary to use the protecting group.
  • an oligopeptide in which the N-terminal amino group is protected by the protecting group P 3 is reacted in the presence of a condensing agent, and the following formula ( Obtain the compound represented by 5).
  • the protecting group P 2 may be deprotected at the same time as the protecting group P 1.
  • Peptide in the following formula (5) is an oligopeptide synonymous with W.
  • the active carbonateizing reagent is not particularly limited, and examples thereof include p-nitrophenylchloroformate and di (N-succinimidyl) carbonate. Note that m3 in the following equation (6) has the same meaning as described above.
  • an carboxylic acid-protected acrylic acid ester is used in the presence of a strong base.
  • a compound represented by the following formula (8) is obtained.
  • m3 in the following formula (8) has the same meaning as described above, and the acrylic acid ester used in the reaction is not particularly limited as long as the number of carbon atoms satisfies m3, but specifically, t-butyl acrylate or the like is used. Be done.
  • the heterobifunctional monodisperse polyethylene glycol of the formula (1) can be produced, for example, by the following steps.
  • the compounds represented by the formulas (7), (8) and (10) all have one amino group, which can be used to convert to the functional group shown as X 1. Is.
  • the step of converting the amino group at the terminal of the heterobifunctional monodisperse polyethylene glycol to another functional group is not particularly limited, but basically has an active ester group capable of reacting with the amino group. It can be converted to various functional groups by using a compound or a general reaction reagent such as an acid anhydride or an acid chloride.
  • the desired product when it is desired to convert the amino group at the terminal of the heterobifunctional monodisperse polyethylene glycol into a maleimide group, the desired product can be obtained by reacting with the following reagent.
  • the desired product when it is desired to convert the amino group at the terminal of the heterobifunctional monodisperse polyethylene glycol into a carboxyl group, the desired product can be obtained by reacting with succinic anhydride or glutaric anhydride.
  • the desired product when it is desired to convert the amino group at the terminal of the heterobifunctional monodisperse polyethylene glycol into a hydroxyl group, the desired product can be obtained by subjecting it to a condensation reaction with a ring-opening product of a cyclic ester such as caprolactone.
  • the compounds represented by the formulas (6), (7), (8) and (9) all have one carboxylic acid, and the compounds represented by the formula (10) are Since it has one hydroxyl group, it can be used to convert it to the functional group shown as Y 1.
  • the step of converting the terminal carboxylic acid of the heterobifunctional monodisperse polyethylene glycol to another functional group is not particularly limited, but for example, a compound capable of converting the carboxylic acid into an active ester group, specifically, a compound capable of converting the carboxylic acid into an active ester group.
  • N-Hydroxysuccinimide and the like can be converted into various functional groups by reacting in the presence of a condensing agent.
  • the step of converting the hydroxyl group at the terminal of the heterobifunctional monodisperse polyethylene glycol to another functional group is not particularly limited, but for example, a compound capable of converting the hydroxyl group to an active carbonate group, specifically, p. -By using an active carbonate-forming reagent such as nitrophenyl chloroformate or di (N-succinimidyl) carbonate, it can be converted into various functional groups.
  • an antibody-drug conjugate comprising a heterobifunctional monodisperse polyethylene glycol represented by the formula (2) is provided.
  • R 1 in the formula (2) of the present invention is a hydrocarbon group or a hydrogen atom having 1 to 7 carbon atoms, and specific hydrocarbon groups include a methyl group, an ethyl group, a propyl group, an isopropyl group and a t-butyl group. , Phenyl group, benzyl group and the like.
  • a preferred embodiment of R 1 is a methyl group or a hydrogen atom, more preferably a methyl group. Note that R 1 in Eq. (2) has the same meaning as described above.
  • N in the formula (2) of the present invention is an integer of 3 to 72, preferably an integer of 4 to 48, and more preferably an integer of 6 to 36, which represents the number of repeating units of the monodisperse polyethylene glycol. Particularly preferably, it is an integer of 8 to 24.
  • n in Eq. (2) has the same meaning as described above.
  • one of X 2 and Y 2 of formula (2) is an antibody and the other is a drug.
  • W, Z and b in the formula (2) of the present invention are synonymous with W, Z and b in the formula (1).
  • a 2 , B 2 and C 2 in the formula (2) of the present invention are divalent spacers, each of which is composed of a covalent bond.
  • a 2 is -L 1 - (CH 2) m1 -L 7 -, - L 1 - (CH 2) m1 -L 8 -, - L 1 - (CH 2) m1 -L 2 - ( CH 2) m2 -L 8 - or -L 8 - represents preferably -L 1 - (CH 2) m1 -L 8 -, - L 1 - (CH 2) m1 -L 2 - (CH 2) m2 -L 8 - or -L 8 - it is.
  • L 1 , L 2 , m 1 and m 2 in the equation have the same meanings as described above.
  • B 2 is -CH 2 -L 9 -, - CH 2 -L 9 - (CH 2) m3 -L 10 -, - CH 2 -L 9 - (CH 2) m3 -L 10 - (CH 2) m4 -L 11 -, - CH 2 -L 12 -, - CH 2 -L 9 - (CH 2) m3 -L 12 - or -CH 2 -L 9 - (CH 2 ) m3 -L 10 - (CH 2 ) m4 -L 12 - it represents, preferably -CH 2 -L 9 - (CH 2 ) m3 -L 10 -, - CH 2 -L 9 - (CH 2) m3 -L 12 - or -CH 2 -L 9 - (CH 2) m3 -L 10 - (CH 2) m4 -L 12 - a, and still more preferably -CH 2 -L 9 - (CH 2 -
  • L 7 , L 9 , L 10 and L 11 in the above formula are independently ether bond, urethane bond, amide bond, secondary amino group or carbonyl group, respectively.
  • L 7 and L 11 are bonds formed with W represented by the above formula (1), and amide bonds or secondary amino groups are preferable independently, and L 9 is an ether bond or urethane. The bond is preferable, and L 10 is preferably a urethane bond, an amide bond or a secondary amino group.
  • It is an atomic group formed between a functional group and a functional group present in the antibody represented by X 2 or Y 2 , specifically, an amide bond, a urethane bond, a maleimide and thiol bond, a thioether bond, and a disulfide bond.
  • C 2 is a functional group contained in X 1 or Y 1 of the heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) in the presence of the peptide linker represented by W, and a functional group present in the antibody or drug. It is an atomic group formed between groups, specifically, amide bond, urethane bond, maleimide and thiol bond, thioether bond, disulfide bond, carbonate bond, ester bond, ether bond, 1H-1,2, 3-Triazole-1,4-diyl structure, secondary amino group, hydrazide group, oxyamide group or hydrocarbon group containing these.
  • an antibody-drug conjugate is a compound represented by the following formula (I) or a salt thereof, in which Ab represents an antibody and D represents a drug.
  • Ab represents an antibody
  • D represents a drug.
  • L represents a linker composed of heterobifunctional monodisperse polyethylene glycol represented by the above formula (1)
  • k represents the number of linker-drug conjugate (DL) units that bind to an antibody.
  • antibody is used in its broadest sense, and specifically includes monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (eg, bispecific antibodies), and the like. And antibody fragments are covered as long as they exhibit the desired biological activity (Miller, K. et al. J. Immunol. 2003, 170, 4854-4861).
  • Antibodies can be derived from mouse antibodies, human antibodies, humanized antibodies, chimeric antibodies, or other species. Antibodies are proteins produced by the immune system that are capable of recognizing and binding to specific antigens (Janeway, C .; Travers, P .; Walport, M .; Shlomchik, M. Immunobiology, 5th ed. Garlan Publishing: New York, 2001).
  • the target antigen generally has a number of binding sites (also called epitopes) recognized by the CDRs on multiple antibodies. Antibodies that specifically bind to different epitopes have different structures. Thus, one antigen may have more than one corresponding antibody.
  • An antibody comprises a full-length immunoglobulin molecule, or an immunologically active portion of a full-length immunoglobulin molecule (ie, a molecule that contains an antigen of interest or an antigen-binding site that immunospecifically binds to that portion).
  • targets include, but are not limited to, cancer cells, or cells that produce autoimmune antibodies associated with autoimmune diseases.
  • the immunoglobulins disclosed herein are immunogens of any type (eg, IgG, IgE, IgM, IgD, and IgA), classes (eg, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclasses. It can be a globulin molecule.
  • the immunoglobulin can be derived from any species. However, in one embodiment, the immunoglobulin is of human, mouse, or rabbit origin.
  • Polyclonal antibodies are heterogeneous populations of antibody molecules, such as those derived from the serum of immunized animals.
  • Various procedures known in the art may be used to generate polyclonal antibodies against the antigen of interest.
  • target antigens or derivatives thereof may be injected to immunize a variety of host animals, including but not limited to rabbits, mice, rats and guinea pigs.
  • Freund's (complete and incomplete) adjuvants mineral gels such as aluminum hydroxide, surface active substances such as litholecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpets
  • surface active substances such as litholecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpets
  • BCG Bacille Calmett-Guerin
  • Corynebacterium u parvum Such adjuvants are also known in the art.
  • Monoclonal antibodies are homogenous antibodies to specific antigenic determinants (eg, cellular antigens (cancer or autoimmune cell antigens), viral antigens, microbial antigens, proteins, peptides, carbohydrates, chemicals, nucleic acids or antigen-binding fragments thereof).
  • mAbs Monoclonal antibodies to the antigen of interest may be prepared using any technique known in the art. These are the hybridoma technique first described by Kohler, G; Milstein, C. Nature 1975, 256, 495-497), the human B cell hybridoma technique (Kozbor, D. et al. Immunol. Today 1983, 4, 72- 79) and EBV-hybridoma techniques (Cole, S. P. C.
  • Such antibodies may be of any immunoglobulin type including IgG, IgM, IgE, IgA and IgD and any subspecies thereof.
  • Hybridomas that produce monoclonal antibodies in the present invention may be cultured in vitro or in vivo.
  • Monoclonal antibodies include, but are not limited to, human monoclonal antibodies, humanized monoclonal antibodies, chimeric monoclonal antibodies and antibody fragments.
  • Human monoclonal antibodies are any of a number of techniques known in the art (eg, Teng, N.N. et al. Proc. Natl. Acad. Sci. USA. 1983, 80, 7308-7312, Kozbor. , D. et al. Immunology Today 1983, 4, 72-79, Olsson, L. et al. Meth. Enzymol. 1982, 92, 3-16, and Proceedings of US Pat. Nos. 5,939,598 and 5770429. See).
  • Recombinant antibodies such as chimeric monoclonal antibodies and humanized monoclonal antibodies, can be made using standard recombinant DNA techniques known in the art (see, eg, US Pat. Nos. 4,816,567, 4816397). ).
  • Resurfacing treatment of an antibody can also reduce the immunogenicity of the antibody (US Pat. No. 5225539, European Patent No. 0239400, 0519596, 0592106). See book).
  • the antibody may be a bispecific antibody.
  • Methods for making bispecific antibodies are known in the art.
  • the conventional method for producing a full-length bispecific antibody utilizes the co-expression of two immunoglobulin heavy chain-light chain pairs when the two strands have different specificities (Milstein, C et al. See Nature 1983, 305, 537-539).
  • a bispecific antibody can be prepared by fusing an antibody variable region having a desired binding specificity (antibody-antigen binding site) with an immunoglobulin invariant region sequence.
  • SCA single chain antibody
  • Any other molecule that has the same specificity as an antibody including scFv, sc-Fv-Fc, FvdsFv, minibody, diabodies, triabodies, tetrabodies, and CDRs, eg domain antibodies. And, but are not limited to, include antibody fragments.
  • known antibodies for the treatment or prevention of cancer may be used. All target proteins can be targeted by the antibody, including any target protein whose expression correlates with cancer, cell growth disorders or tumor expression on cells.
  • the antibody is useful in the treatment of cancer.
  • antibodies available for the treatment of cancer are Ritzan®® (Genentech), a chimeric anti-CD20 monoclonal antibody for the treatment of patients with non-Hodikin lymphoma, and mouse antibodies for the treatment of ovarian cancer.
  • Ovalex (Altarex), Panorex (GraxoWelcome), a mouse IgG2a antibody for the treatment of conjunctival cancer, anti-EGFR for the treatment of epithelial cell growth factor-positive cancers such as head and neck cancers Setuximabu erbitux (Imclon Systems), an IgG chimeric antibody, Vitaxin (Medimune), a humanized antibody for the treatment of sarcoma, and humanized IgG1 antibody for the treatment of chronic lymphocytic leukemia (CLL).
  • CLL chronic lymphocytic leukemia
  • the antibody is an antibody against the following antigens.
  • Some specific useful antibodies are BR96 mAb (Trail, P. A. et al. Science 1993, 261, 212-215), BR64 (Trail, P. A. et al. Cancer Research 1997, 57, 100-105), mAbs for CD40 antibodies such as S2C6 mAbs (Francisco, J. A. et al. Cancer Res. 2000, 60, 3225-3231), or US Patent Application Publication Nos. 2003/0211 100 and 2002 / 0142358
  • Other anti-CD40 antibodies as disclosed, mAbs against CD70 antibodies such as 1F6 mAb and 2F2 mAb, and AC10 (Bowen, M. A. et al. J. Immunol.
  • Drugs that can be used in the present invention include chemotherapeutic agents.
  • Chemotherapeutic agents are useful compounds in the treatment of cancer.
  • Examples of chemotherapeutic agents include: alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN TM); alkyl sulfonates such as busulfan, improsulfan.
  • calicheamicin in particular calicheamicin gamma 1 and calicheamicin theta I, eg Angelw Chem Intl. Ed. Engl. 33: 183-186 (1994); including dynemicin, dynemycin A; Esperamicin; as well as neocarzinostatin chromophore and related pigment proteins enesiin antibiotics chromophores, aclacinomysins, actinomycin, authramycin, azaserin ( azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin; chromomycins, dactinomycin, daunorbisin (azaserine), bleomycins (bleomycins), cactinomycin (cactinomycin), carabicin (carabicin), carminomycin (carminomycin), carzinophilin (carzinophilin); daunorubi
  • Antihormonal agents that act to regulate or inhibit the action of hormones on tumors, such as: tamoxifen, raloxifene, inhibit aromatase 4 (5) -imidazoles, 4 -Anti-estrogen drugs including hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgen drugs such as flutamide. ), Nilutamide, bicalutamide, leuprolide, and goserelin; siRNA and any of the above pharmaceutically acceptable salts, acids, or derivatives.
  • Other chemotherapeutic agents that can be used with the present invention are disclosed in US Patent Application Publication No. 2008/0171040 or US Patent Application Publication No. 2008/0305044, which are incorporated herein by reference.
  • the chemotherapeutic agent is a small molecule drug.
  • the low molecular weight drug preferably has a molecular weight of 100 to 1500, more preferably 120 to 1200, and even more preferably 200 to 1000. It is widely used to refer to organic, inorganic, or organometallic compounds that typically have a molecular weight of less than about 1000.
  • the small molecule drugs of the present invention also include oligopeptides and other biomolecules having a molecular weight of less than about 1000. Small molecule drugs are well characterized in the art, for example, in WO 05/058367, European Patent Application Publications 85901495 and 8590319, and in US Pat. No. 4,956,303. We will use them as they are.
  • the preferred small molecule drug of the present invention is a small molecule drug that can be linked to an antibody.
  • the present invention includes known and potentially known drugs.
  • Particularly preferred small molecule drugs include cytotoxic drugs.
  • Preferred cytotoxic drugs are maytansinoids, CC-1065 analogs, morpholinos, doxorubicins, taxanes, cryptophycins, epothilones, calicheamicins. ), Auristatins, and pyrrolobenzodiazepine dimers.
  • the antibody-drug conjugate containing the heterobifunctional monodisperse polyethylene glycol represented by the formula (2) of the present invention can be used with the antibody using the heterobifunctional monodisperse polyethylene glycol represented by the formula (1). It can be prepared by binding the drug.
  • the method for preparing the antibody-drug conjugate represented by the formula (2) may be prepared by binding the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) to the drug and then binding the antibody.
  • the heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) may be bound to an antibody and then a drug may be bound to prepare the antibody. Further, purification may be performed after binding either the antibody or the drug, or purification may be performed after binding both the antibody and the drug.
  • the compound in which the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) is bound to a drug can be used as a purification means such as column chromatography, extraction, recrystallization, adsorbent treatment, reprecipitation, supercritical extraction and the like. Can be purified. Further, the compound in which the heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) is bound to the antibody and the antibody-drug conjugate in which both the antibody and the drug are bound are, for example, column chromatography, extraction and adsorption. It can be purified by purification means such as agent treatment.
  • a linker-drug conjugate in which a heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) is bound to a drug can be prepared by using a standard conjugation technique known in the art (for example,). See U.S. Patent Application Publication Nos. 8163888, 7569241, 7498298 and International Publication 2011/023883, 2005/112919).
  • the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) or the linker consisting of the linker and the drug-the conjugate of the drug conjugate and the antibody is represented by the atomic group X 1 or Y 1 in the formula (1). It can be synthesized under conditions where the functional groups contained react with the functional groups in the antibody to form covalent bonds. Also, in general, the chemical reactions used cannot alter the integrity of the antibody, eg, the target binding ability of the antibody. Preferably, the binding properties of the conjugated antibody are similar to those of the non-conjugated antibody.
  • heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) or a linker-drug conjugate consisting of the linker and a drug is bound to an antibody using a chemical reaction and technique known in the art.
  • Can be made for example, "Arnon, R. et al .; Monoclonal antibodies as carriers for immunotargeting of drugs; Monoclonal antibodies for cancer detection and therapy. Academic Press; Baldwin, RW et al. Eds .; L -382 "," Hellstrom, K. E. et al .; Antibodies for drug delivery .; Controlled Drug Delivery; Robinson, JR et al.
  • the heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) or a linker-drug conjugate composed of the linker and the drug can be bound to the side chain of the amino acid residue of the antibody.
  • the bond formed by reaction with the antibody is a bond formed with the amino group of the antibody, eg, an amide bond, a thioether bond, and a thiourea bond, preferably an amide bond. Is.
  • the bond formed by the reaction with the antibody is a bond formed with the thiol group of the antibody, eg, an amide bond, a maleimide-thiol bond, a thioether bond, and a thiourea bond. Yes, preferably a maleimide-thiol bond and a thioether bond.
  • the binding of the heterobifunctional monodisperse polyethylene glycol or linker-drug conjugate of the invention to the antibody is the binding of maleimide to thiol resulting from the reaction of the antibody with an interchain cysteine residue. Or it is a thioether bond.
  • an average of 8 drugs can be bound per antibody by reacting with the cysteine residue produced by reducing the 4 pairs of interchain disulfide bonds of the antibody. desirable.
  • Heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) or a functional group for linking a linker-drug conjugate consisting of the linker and a drug to a primary amino group of an available lysine residue is known.
  • examples thereof include, but are not limited to, an NHS-ester group, an N-succinimidyl carbonate group, and a p-nitrophenyl carbonate group.
  • Heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) or a functional group for linking a linker-drug conjugate consisting of the linker and a drug to a free thiol group of an available cysteine residue is known. Yes, but not particularly limited, examples thereof include ⁇ -haloacetyl group and maleimide group.
  • the functional group of the heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) or the antibody that reacts with the linker-drug conjugate consisting of the linker and the drug is limited to the side chain group of the naturally occurring amino acid. Instead, it can be converted to another useful functional group by reacting the amino acid side chain of the antibody with a suitable small molecule.
  • the side chain of an amino acid, such as an amino group can be converted to another useful functional group, such as a hydroxy group, by reacting a suitable small molecule with the amino group.
  • an amino acid may be introduced at an arbitrary position of the antibody by genetic engineering operation, and the introduced amino acid may be either a natural type or a non-natural type.
  • Genetic engineering techniques for introducing amino acid residues into antibodies include, for example, "Axup, JY et al. Proc Natl Acad Sci. 2012, 109: 16101-16106" and "Tian, F. et al. Proc Natl Acad.” Sci. 2014, 111: 1766-1771 ”.
  • the heterobifunctional monodisperse polyethylene glycol represented by the above formula (1) or a linker-drug conjugate composed of the linker and a drug may be site-nonspecifically or site-specifically bound to the antibody. Either may be used, but a site-specific conjugation is preferable.
  • ADC antibody-drug conjugate
  • a heterobifunctional monodisperse polyethylene glycol represented by the formula (2) of the present invention is described in "Hamblett, K. J. et al. Clin. Cancer Res. 2004, 10: 7063-7070 ”,“ Doronina, SO et al. Nat Biotechnol. 2003, 21: 778-784 ”,“ Francisco, JA et al. Blood, 2003, 102: 1458-1465 ”,“ Chari, RVJ et al Can be prepared by a standard method similar to the method described in "Cancer Res. 1992, 52: 127-131" and “Tumey, LN et al. ACS Med. Chem. Lett. 2016, 7: 977-982".
  • an ADC in which the linker-drug conjugate of the invention binds to an interchain cysteine residue of an antibody and has eight drugs per antibody is dithiothreitol (DTT) or tris (2-carboxyethyl) phosphine (TCEP). ) Is used in excess to partially reduce the antibody at 37 ° C. for 1 hour, then consisting of an excess of heterobifunctional monodisperse polyethylene glycol represented by the formula (1) and the drug. The reaction can be quenched by the addition of a linker-drug conjugate, eg, 15 equivalents, at 20 ° C.
  • DTT dithiothreitol
  • TCEP (2-carboxyethyl) phosphine
  • the obtained ADC mixture can be purified by removing desalted and unreacted linker-drug conjugates by gel filtration chromatography using NAP®-5 equilibrated with PBS. It can be further purified by size exclusion chromatography. The resulting ADC may then be sterilized and filtered using, for example, a 0.2 ⁇ m filter and lyophilized for storage.
  • the number of drugs per antibody in ADC can be determined by methods known to those skilled in the art, such as UV / visible spectroscopy, mass spectrometry, ELISA, electrophoresis, HPLC, and combinations thereof (eg,). , “Chen, J. et al. Anal. Chem. 2013, 85: 1699-1704", “Valliere-Douglass, JF et al. Anal. Chem. 2012, 84: 2843-2849", “Birdsall, RE et al” . mABs, 2015, 7: 1036-1044 ”and“ Zhao, RY et al. J. Med. Chem. 2011, 54: 3606-3623 ”).
  • the average number of drugs for one antibody in the ADC can be calculated by UV / Visible spectroscopy. Specifically, it can be calculated by measuring the UV absorbance of the antibody-drug conjugate aqueous solution at two different wavelengths, for example, 280 nm and 495 nm, and then performing the following calculation. Since the total absorbance at a certain wavelength is equal to the sum of the absorbances of all the absorbed chemical species existing in the system [absorbance additive], the molar absorbance coefficient of the antibody and the drug is calculated before and after the compounding reaction of the antibody and the drug. Assuming that there is no change, the antibody concentration and the drug concentration in the antibody-drug complex are expressed by the following relational expressions.
  • A280 ⁇ D, 280CD + ⁇ A, 280CA Equation (i)
  • A495 ⁇ D, 495CD + ⁇ A, 495CA Equation (ii)
  • DAT CD / CA equation (iii)
  • A280 shows the absorbance of the antibody-drug complex aqueous solution at 280 nm
  • A495 shows the absorbance of the antibody-drug complex aqueous solution at 495 nm
  • ⁇ A, 280 shows the molar absorbance coefficient of the antibody at 280 nm
  • ⁇ A, 495 shows the molar absorbance coefficient of the antibody at 495 nm.
  • ⁇ D indicates the molar absorbance of the linker-drug conjugate at 280 nm
  • ⁇ D indicates the molar absorbance of the linker-drug conjugate at 495 nm
  • CA indicates the antibody-drug complex.
  • the antibody concentration in the body is indicated
  • the CD indicates the drug concentration in the antibody-drug complex. Estimates are used for ⁇ A, 280 and ⁇ A, 495, and ⁇ A, 495 is usually 0.
  • CA and CD can be obtained by measuring A280 and A495 of the antibody-drug conjugate aqueous solution and substituting these values into equations (i) and (ii) to solve simultaneous equations.
  • the average number of drug bonds per antibody can be obtained by dividing CD by CA.
  • the number of drugs bound to an antibody via the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) of the present invention is, for example, the number of drugs per antibody. Defined by the average number of.
  • the number of bonds thereof is the reactivity on the antibody with which the linker or the linker-drug conjugate reacts. It can be determined by the number of sites. The reactive sites on the antibody need not be completely blocked, and conjugates having different numbers of drugs bound to the antibody may be mixed in the prepared ADC.
  • the number of drugs that bind to one antibody may be the average value of the distribution or a single value, but the smaller or less the distribution stabilizes the physical characteristics of the ADC. It is preferably a single value. Therefore, k in the above equation (I) represents a number or an integer having a distribution that is not an integer.
  • the number of drugs bound per antibody is preferably 1 to 20, more preferably 2 to 16, still more preferably 3 to 12, and particularly preferably 4 to 8. And most preferably 8.
  • the heterobifunctional monodisperse polyethylene glycol of the present invention is required to have the ability to specifically decompose intracellularly and effectively release the drug slowly.
  • the following tests were carried out to determine the intracellular degradability of the heterobifunctional monodisperse polyethylene glycol and the intracellular of the drug to which the linker was bound. The activity can be evaluated.
  • the test method for evaluating the degradability of the heterobifunctional monodisperse polyethylene glycol by an intracellular enzyme is not particularly limited, but for example, the linker can be used using a lysosomal enzyme which is an intracellular enzyme. Examples include tests that confirm the degradation of the bound model compound or drug. Specifically, if the lysosomal enzyme is catepsin B, a model in which the heterobifunctional monodisperse polyethylene glycol is bound to a catepsin B / DTT solution prepared by adding the reducing agent DTT to catepsin B.
  • Degradability can be confirmed by adding a solution containing a compound or a drug, incubating at 37 ° C., performing HPLC measurement of the sampled solution, and comparing the charts before and after the test. Furthermore, if there is a new peak, the cleavage site of the linker and the structure of the released model compound or drug can be confirmed by confirming the mass chromatogram.
  • the model compound used in the test is not particularly limited, but when the heterobifunctional monodisperse polyethylene glycol has a maleimide group as a functional group, the cysteine residue of catepsin B reacts with the maleimide group to form an enzyme.
  • a model compound that reacts with a maleimide group and examples thereof include a compound having a thiol group, specifically, glutathione and the like.
  • the drug used in the test is not particularly limited as long as it is the drug shown above, and examples thereof include a drug having an amino group, specifically, doxorubicin and the like.
  • test method for evaluating the intracellular pharmacological activity of the drug-linker compound to which the heterobifunctional monodisperse polyethylene glycol is bound is not particularly limited, but for example, the drug-linker compound can be used. Examples thereof include a cytotoxicity test in which cells are cultured using the contained medium and the cell viability is calculated.
  • the peptide linker introduced into the heterobifunctional monodisperse polyethylene glycol of the present invention is not degraded intracellularly, it is possible that the binding to the drug is not degraded intracellularly and the activity of the drug is reduced. The higher the cell viability, the lower the activity of the drug. Therefore, by calculating the cell viability by this test and comparing it with the cell viability of the control drug-linker compound containing no peptide linker, The intracellular drug activity by using the heterobifunctional monodisperse polyethylene glycol of the present invention can be evaluated.
  • the cells and medium used here are not particularly limited, but specifically, the drug-linker compound is dissolved in the medium RPMI-1640, HeLa cells are cultured at 37 ° C., and then a viable cell count measurement kit is used.
  • the cell viability can be calculated by performing a color reaction using the cells and further measuring the absorbance.
  • the cell viability is calculated by dividing the absorbance of the sample, which is obtained by subtracting the absorbance of the blank, by the absorbance of only the cells that do not contain the sample.
  • the oligopeptide introduced into the heterobifunctional monodisperse polyethylene glycol of the present invention is required to have a more hydrophilic property that does not interfere with the shielding effect of the hydrophobic drug by the linker.
  • the following tests can be carried out to evaluate the hydrophilicity of the heterobifunctional monodisperse polyethylene glycol.
  • the test method for evaluating the hydrophilicity of the peptide in the heterobifunctional monodisperse polyethylene glycol is not particularly limited, but size exclusion chromatography (SEC), ion exchange chromatography (IEC), reverse phase ( It can be evaluated by methods known to those skilled in the art, such as HPLC by RP) chromatography and hydrophobic interaction chromatography (HIC) (eg, "Mant, CT et al. Methods Mol Biol. 2007, 386: 3-55". See).
  • the hydrophilicity of the peptide can be evaluated by measuring the target compound under the same conditions using reverse phase HPLC and comparing the retention times of the peak tops. In the case of reverse phase HPLC, the higher the hydrophilicity of the target compound, the shorter the retention time is detected.
  • JNM-ECP400 or JNM-ECA600 manufactured by JEOL Datum Co., Ltd. was used.
  • a ⁇ 5 mm tube was used for the measurement, and when the deuterated solvent was CD Cl 3 , CD 2 Cl 2 or DMSO-d6, tetramethylsilane (TMS) was used as the internal standard substance.
  • dichloromethane was distilled off under reduced pressure, 400 g / L sodium hydroxide aqueous solution (0.869 g, 6.60 mmol) was added, and the reaction was carried out at 25 ° C. for 1 hour. went.
  • the reaction mixture was washed with toluene and dichloromethane, salt was dissolved in an aqueous layer to form a 15 wt% saline solution, and extraction was performed using dichloromethane.
  • Acetonitrile was added to the organic layer, and the mixture was washed with water using a 5 wt% sodium carbonate aqueous solution containing 15 wt% salt, and then washed with 0.2 M hydrochloric acid containing 20 wt% salt.
  • the organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the compound of formula (16).
  • the aqueous layer adjusted to pH 10 with a 400 g / L sodium hydroxide aqueous solution was washed with toluene, and then the pH of the aqueous layer was adjusted to pH 2.5 with 6N hydrochloric acid. Salt was dissolved in the aqueous layer so as to be a 15 wt% saline solution, and extraction was performed using chloroform.
  • the organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the compound of formula (17).
  • the reaction solution was washed with 0.2 M citrate phosphate buffer (pH 2.4) containing 20 wt% salt, the organic layer was concentrated, and the residue was dissolved in 0.2 M citrate phosphate buffer (pH 3.0). After washing the aqueous layer with toluene, extraction was performed on the organic layer using toluene and chloroform. The organic layer was washed with 20 wt% brine, dried over anhydrous magnesium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the compound of formula (18).
  • dichloromethane was distilled off under reduced pressure, 400 g / L sodium hydroxide aqueous solution (0.150 g, 1.11 mmol) was added, and the reaction was carried out at 25 ° C. for 1 hour. went.
  • the reaction mixture was washed with toluene and dichloromethane, and then extracted with dichloromethane. After washing with water using a 5 wt% sodium carbonate aqueous solution containing 15 wt% salt, further washing was performed with 0.2 M hydrochloric acid containing 20 wt% salt.
  • the aqueous layer adjusted to pH 10 with a 400 g / L aqueous sodium hydroxide solution was washed with toluene and chloroform, and then the pH of the aqueous layer was adjusted to pH 2.5 with 6N hydrochloric acid. Salt was dissolved in the aqueous layer so as to be a 10 wt% saline solution, and extraction was performed using chloroform.
  • the organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the compound of formula (23).
  • the reaction solution was washed with 0.2 M citrate phosphate buffer (pH 2.4) containing 20 wt% salt, the organic layer was concentrated, and the residue was dissolved in 0.2 M citrate phosphate buffer (pH 3.0). After washing the aqueous layer with toluene and chloroform, extraction was performed on the organic layer using toluene and chloroform. The organic layer was washed with 20 wt% brine, dried over anhydrous magnesium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the compound of formula (24).
  • the reaction mixture was washed with toluene and dichloromethane, salt was dissolved in an aqueous layer to form a 15 wt% saline solution, and extraction was performed using dichloromethane.
  • Acetonitrile was added to the organic layer, and the mixture was washed with water using a 5 wt% sodium carbonate aqueous solution containing 15 wt% salt, and then washed with 0.2 M hydrochloric acid containing 20 wt% salt.
  • the organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the compound of formula (27).
  • the aqueous layer adjusted to pH 10 with a 400 g / L sodium hydroxide aqueous solution was washed with toluene, and then the pH of the aqueous layer was adjusted to pH 2.5 with 6N hydrochloric acid. Salt was dissolved in the aqueous layer so as to be a 15 wt% saline solution, and extraction was performed using chloroform.
  • the organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the compound of formula (29).
  • the aqueous layer adjusted to pH 10 with a 400 g / L aqueous sodium hydroxide solution was washed with toluene and chloroform, then the saline solution was dissolved in the aqueous layer to make a 15 wt% saline solution, and extraction was performed using chloroform.
  • the organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the compound of formula (35).
  • the organic layer was washed with 0.15 M borate buffer (pH 10) containing 10 wt% salt and a 5 wt% sodium dihydrogen phosphate aqueous solution containing 20 wt% salt, dried over anhydrous sodium sulfate, filtered, and the solvent was distilled under reduced pressure. I left. The residue was dissolved in acetonitrile, washed with hexane and t-butanol, and the solvent was evaporated under reduced pressure to give the compound of formula (37).
  • 0.15 M borate buffer (pH 10) containing 10 wt% salt and a 5 wt% sodium dihydrogen phosphate aqueous solution containing 20 wt% salt
  • the organic layer was washed with 0.15 M borate buffer (pH 10) containing 10 wt% salt and a 5 wt% sodium dihydrogen phosphate aqueous solution containing 20 wt% salt, dried over anhydrous sodium sulfate, filtered, and the solvent was distilled under reduced pressure. I left. The residue was dissolved in acetonitrile, washed with hexane and t-butanol, and the solvent was evaporated under reduced pressure to give the compound of formula (38).
  • 0.15 M borate buffer (pH 10) containing 10 wt% salt and a 5 wt% sodium dihydrogen phosphate aqueous solution containing 20 wt% salt
  • Example 30 Compound 33 of compound 33 and doxorubicin
  • Doxorubicin hydrochloride (2.53 mg, 4.36 ⁇ mol), N, N-diisopropylamine (1.50 mg, 11.1 ⁇ mol), N, N-dimethylformamide, and the compound of formula (33) in a 4 ml screw tube containing a stir bar (33). 10.0 mg, 4.84 ⁇ mol) was charged, and the reaction was carried out at 25 ° C. for 4 hours. After that, purification was carried out in the same manner as in Example 29 to obtain a drug-linker compound of the formula (40).
  • Example 32 compound 38 and doxorubicin conjugate
  • Doxorubicin hydrochloride (2.53 mg, 4.36 ⁇ mol), N, N-diisopropylamine (1.50 mg, 11.1 ⁇ mol), N, N-dimethylformamide, and the compound of formula (38) in a 4 ml screw tube containing a stir bar (38). 10.4 mg, 4.84 ⁇ mol) was charged, and the reaction was carried out at 25 ° C. for 4 hours. Then, purification was carried out in the same manner as in Example 31 to obtain a drug-linker compound of the formula (42).
  • the average number of bonds per antibody in an antibody-drug conjugate can be calculated by measuring the UV absorbance of the antibody-drug conjugate aqueous solution at two wavelengths of 280 nm and 495 nm and then performing the following calculation. Since the total absorbance at a certain wavelength is equal to the sum of the absorbances of all the absorbed chemical species existing in the system [absorbance additive], the molar absorbance coefficient of the antibody and the drug is calculated before and after the compounding reaction of the antibody and the drug. Assuming that there is no change, the antibody concentration and the drug concentration in the antibody-drug complex are expressed by the following relational expressions.
  • A280 shows the absorbance of the antibody-drug complex aqueous solution at 280 nm
  • A495 shows the absorbance of the antibody-drug complex aqueous solution at 495 nm
  • AA, 280 shows the absorbance of the antibody at 280 nm
  • AA, 495 shows the absorbance of the antibody at 495 nm.
  • AD, 280 indicates the absorbance of the drug-linker compound at 280 nm
  • AD, 495 indicates the absorbance of the drug-linker compound at 495 nm
  • ⁇ A, 280 indicates the molar absorbance coefficient of the antibody at 280 nm.
  • ⁇ A, 495 indicate the molar absorbance of the antibody at 495 nm
  • ⁇ D, 280 indicates the molar absorbance of the drug-linker compound at 280 nm
  • ⁇ D, 495 indicates the molar absorbance of the drug-linker compound at 495 nm
  • CA Indicates the antibody concentration in the antibody-drug complex
  • CD indicates the drug concentration in the antibody-drug complex.
  • ⁇ A, 280, ⁇ A, 495, ⁇ D, 280, ⁇ D, 495 values prepared in advance (estimated values or measured values obtained from UV measurement of the compound) are used.
  • ⁇ A, 495 is usually zero.
  • Can be obtained by CA and CD can be obtained by measuring A280 and A495 of the antibody-drug conjugate aqueous solution and substituting these values into equations (i) and (ii) to solve simultaneous equations.
  • Example 36 Calculation of average number of drug bonds per antibody of ADC using compound 41
  • Example 37 Degradability test of compounds 20 and 44 using cathepsin B
  • the compound of formula (20) obtained in Example 10 and the compound of formula (44) obtained in Comparative Example 2 were subjected to a peptide degradability test using cathepsin B, which is a proteolytic enzyme in lysosomes.
  • cathepsin B which is a proteolytic enzyme in lysosomes.
  • a 4 ml screw tube is charged with 25 mM sodium acetate / 1 mM EDTA aqueous solution (0.500 ml) adjusted to pH 5 with acetic acid in human liver-derived catepsin B buffer (25 ⁇ g, ⁇ 1500 units / mg protein, manufactured by Sigma-Aldrich), and catepsin.
  • a diluted B solution was obtained.
  • a 4 ml screw tube is charged with a diluted solution of catepsin B (0.160 ml) and a 30 mM DTT / 25 mM sodium acetate / 15 mM EDTA aqueous solution (0.320 ml) adjusted to pH 5, allowed to stand at 25 ° C for 15 minutes, and then added to 37 ° C in advance.
  • a warm pH 5 25 mM sodium acetate / 1 mM EDTA aqueous solution (1.32 ml) and an aqueous solution (0.200 ml) containing 0.1 mg / ml of the compound of formula (20) or formula (44) were mixed.
  • the compound of formula (20) of the present invention was detected at a retention time of 12.9 minutes in the chart of FIG. 1, but new peaks were detected at retention times of 10.9 minutes and 7.7 minutes after the test with cathepsin B. From the results of the mass chromatogram of FIG. 2, the molecular weight of the new peak was consistent with the fragment decomposed at the C-terminal of glycine of the compound of formula (20). On the other hand, the compound of the formula (44), which is a comparative example, was detected at a retention time of 11.9 minutes in the chart of FIG. 3, and no new peak was detected even after the test with cathepsin B.
  • Example 38 Degradability test of compounds 21 and 26 using cathepsin B
  • the compound of formula (21) obtained in Example 11 and the compound of formula (26) obtained in Example 16 were subjected to a peptide degradability test using cathepsin B, which is a proteolytic enzyme in lysosomes. After that, the degradability test and the HPLC measurement were carried out under the same conditions as in Example 37. Charts of measurement results are shown in FIGS. 4 to 6.
  • the compound of the formula (21) of the present invention was detected at the retention time of 13.8 minutes in the chart of FIG. 4, but new peaks were detected at the retention times of 13.6 minutes and 7.5 minutes after the test with cathepsin B.
  • Example 39 Degradability test of drug-linker compounds 40 and 46 using cathepsin B
  • the test was performed. After that, the test was carried out in the same manner as in Example 37, and HPLC measurement was carried out under the following measurement conditions. Charts of measurement results are shown in FIGS. 7 to 9. As a result, the drug-linker compound of the formula (40) of the present invention was detected at a retention time of 16.8 minutes in the chart of FIG.
  • the heterobifunctional monodisperse polyethylene glycol of the present invention has a para-aminobenzyl alcohol group at the C-terminal of the peptide
  • the para-aminobenzyl alcohol group is also eliminated by cleaving the peptide linker to release the drug. It was found that it can be released in a chemically unmodified structure.
  • Example 40 Degradability test of drug-linker compounds 42 and 46 using cathepsin B
  • the heterobifunctional monodisperse polyethylene glycol of the present invention has a para-aminobenzyl alcohol group at the C-terminal of the peptide
  • the para-aminobenzyl alcohol group is also eliminated by cleaving the peptide linker to release the drug. It was found that it can be released in a chemically unmodified structure.
  • Example 41 Cytotoxicity test using drug-linker compounds 40 and 46
  • medium RPMI-1640 10% FBS Pn / St
  • 80% confluent cells of HeLa cells prepare cell suspension to 5000 cells / well, and add cell suspension to each plate of the 96-well microplate. Dispensed. After culturing in a carbon dioxide incubator for 24 hours, the medium was exchanged, and the drug-linker compound of formula (40) obtained in Example 30 or the compound of formula (46) obtained in Comparative Example 4 was dissolved at various concentrations. Medium was added and the cells were cultured at 37 ° C. for 24 hours.
  • a Cell Counting Kit-8 solution (manufactured by Dojin Chemical Co., Ltd.) was added to each well of the microplate, and a color reaction was carried out in a carbon dioxide incubator for 2 hours.
  • the absorbance at 450 nm was measured with a microplate reader, the cell viability was calculated by the following formula, and the cytotoxicity of the drug was evaluated.
  • the cell viability at each concentration is shown in FIG.
  • Cell viability (%) [(A sample- A blank ) / (A cell- A blank )] x 100
  • a sample Absorbance of the sample
  • a cell Absorbance of cells only without sample
  • a blank Absorbance of cell-free blank
  • the drug-linker compound of the formula (40) of the present invention showed cytotoxicity because the cell viability decreased in a sample concentration-dependent manner.
  • the compound of the formula (46), which is a comparative example had a high cell viability even under the condition of a high sample concentration and did not show cytotoxicity.
  • the drug-linker compound using the heterobifunctional monodisperse polyethylene glycol of the present invention has higher cytotoxicity than the drug-linker compound of the comparative example containing no peptide linker, and the drug can be released intracellularly. Do you get it.
  • Example 42 Cytotoxicity test using drug-linker compounds 42 and 46
  • medium RPMI-1640 10% FBS Pn / St
  • 80% confluent cells of HeLa cells prepare cell suspension to 5000 cells / well, and add cell suspension to each plate of the 96-well microplate. Dispensed. After culturing in a carbon dioxide incubator for 24 hours, the medium was exchanged, and the drug-linker compound of formula (42) obtained in Example 32 or the compound of formula (46) obtained in Comparative Example 4 was dissolved at various concentrations. Medium was added and the cells were cultured at 37 ° C. for 24 hours.
  • a Cell Counting Kit-8 solution (manufactured by Dojin Chemical Co., Ltd.) was added to each well of the microplate, and a color reaction was carried out in a carbon dioxide incubator for 2 hours.
  • the absorbance at 450 nm was measured with a microplate reader, the cell viability was calculated by the following formula, and the cytotoxicity of the drug was evaluated.
  • the cell viability at each concentration is shown in FIG.
  • Cell viability (%) [(A sample- A blank ) / (A cell- A blank )] x 100
  • a sample Absorbance of the sample
  • a cell Absorbance of cells only without sample
  • a blank Absorption of cell-free blank
  • the drug-linker compound using the heterobifunctional monodisperse polyethylene glycol of the present invention contained a peptide linker. It was found that the cytotoxicity was higher than that of the drug-linker compound of the comparative example which did not contain the drug, and the drug could be released intracellularly.
  • the heterobifunctional monodisperse polyethylene glycol of the present invention was released from the drug by being cleaved by an enzyme in the cell, and suppressed the decrease in pharmacological activity due to the presence of the linker in a bound state.
  • the peptide linker is decomposed by an intracellular enzyme to release the drug slowly, and the hydrophobicity of the drug is effectively shielded by two adjacent monodisperse polyethylene glycols. Since it has a chain, it is useful for modifying biofunctional molecules such as bioactive proteins, peptides, antibodies, nucleic acids and small molecule drugs, drug carriers in drug delivery systems, or diagnostic materials and medical devices.
PCT/JP2020/036195 2019-09-26 2020-09-25 ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール WO2021060439A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202080067753.8A CN114450324B (zh) 2019-09-26 2020-09-25 具有肽连接子的异双官能单分散聚乙二醇
JP2021549023A JPWO2021060439A1 (US08088387-20120103-C00002.png) 2019-09-26 2020-09-25
EP20868583.4A EP4036149A4 (en) 2019-09-26 2020-09-25 HETEROBIFUNCTIONAL MONODISPERSPERED POLYETHYLENE GLYCOL WITH PEPTIDE LINKER
US17/762,719 US20220362397A1 (en) 2019-09-26 2020-09-25 Heterobifunctional monodispersed polyethylene glycol having peptide linker
KR1020227013431A KR20220069989A (ko) 2019-09-26 2020-09-25 펩티드 링커를 갖는 헤테로 2작용성 단분산 폴리에틸렌글리콜
CA3156027A CA3156027A1 (en) 2019-09-26 2020-09-25 HETEROBIFUNCTIONAL MONODISPERSE POLYETHYLENE GLYCOL HAVING A PEPTIDE LINKER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019176066 2019-09-26
JP2019-176066 2019-09-26

Publications (1)

Publication Number Publication Date
WO2021060439A1 true WO2021060439A1 (ja) 2021-04-01

Family

ID=75166215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/036195 WO2021060439A1 (ja) 2019-09-26 2020-09-25 ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール

Country Status (7)

Country Link
US (1) US20220362397A1 (US08088387-20120103-C00002.png)
EP (1) EP4036149A4 (US08088387-20120103-C00002.png)
JP (1) JPWO2021060439A1 (US08088387-20120103-C00002.png)
KR (1) KR20220069989A (US08088387-20120103-C00002.png)
CN (1) CN114450324B (US08088387-20120103-C00002.png)
CA (1) CA3156027A1 (US08088387-20120103-C00002.png)
WO (1) WO2021060439A1 (US08088387-20120103-C00002.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023095741A1 (ja) * 2021-11-25 2023-06-01 日油株式会社 医療用４分岐型水溶性ポリマー

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4956303A (en) 1986-04-28 1990-09-11 Antibody Technology Limited Secondary antibodies against complexes of small molecules and binding partners therefor, their preparation, and their use in diagnostic methods
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0239400B1 (en) 1986-03-27 1994-08-03 Medical Research Council Recombinant antibodies and methods for their production
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
US20020142358A1 (en) 2000-04-28 2002-10-03 Toshifumi Mikayama Human anti-CD40 antibodies and methods of making and using same
US20030211100A1 (en) 2001-11-09 2003-11-13 Vahe Bedian Antibodies to CD40
US20040006215A1 (en) 2002-01-09 2004-01-08 Tibor Keler Human monoclonal antibodies against CD30
EP0592106B1 (en) 1992-09-09 2004-11-24 Immunogen Inc Resurfacing of rodent antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO2005058367A2 (en) 2003-12-16 2005-06-30 Nektar Therapeutics Al, Corporation Pegylated small molecules
WO2005108463A2 (en) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US20080171040A1 (en) 2004-06-01 2008-07-17 Genentech, Inc. Antibody-drug conjugates and methods
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2011023883A1 (fr) 2009-08-25 2011-03-03 Sanofi-Aventis Conjugues de dimeres de pyrrolo [1, 4 ] benzodiazepine en tant qu' anticancereux
US8163888B2 (en) 2003-10-10 2012-04-24 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
WO2018181059A1 (ja) * 2017-03-30 2018-10-04 日油株式会社 ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体
WO2019176875A1 (ja) * 2018-03-13 2019-09-19 日油株式会社 主鎖および側鎖に単分散ポリエチレングリコールを有するヘテロ二官能性化合物
JP2019176066A (ja) 2018-03-29 2019-10-10 アオイ電子株式会社 半導体装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475837C (zh) * 2004-06-11 2009-04-08 北京键凯科技有限公司 多叉分支的聚乙二醇-氨基酸寡肽及其活性衍生物和药物结合物
AU2005254736B2 (en) * 2004-06-18 2011-08-18 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of HIV infections
WO2006088248A1 (ja) * 2005-02-18 2006-08-24 Nof Corporation ポリオキシアルキレン誘導体
CN101168594B (zh) * 2006-10-24 2011-07-27 北京键凯科技有限公司 寡肽为骨架的聚乙二醇活性衍生物、其制备方法及与药物分子的结合物
DE102009050170B4 (de) 2009-10-21 2013-08-01 Diehl Ako Stiftung & Co. Kg Hausautomatisierungs- und Hausinformationssystem
JP5825507B2 (ja) * 2010-06-25 2015-12-02 日油株式会社 分岐型ヘテロポリエチレングリコール
AU2012301793A1 (en) * 2011-08-30 2014-03-20 Quanta Biodesign, Ltd. Branched discrette PEG constructs
WO2014177042A1 (zh) * 2013-04-28 2014-11-06 Qin Gang 一种新型的连接子及其制备方法和用途
CN104448295B (zh) * 2013-12-02 2018-01-23 北京键凯科技股份有限公司 聚乙二醇‑多爪寡肽键合的雷帕霉素衍生物
CN104109235B (zh) * 2014-05-30 2017-07-18 厦门赛诺邦格生物科技股份有限公司 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质
JP6248875B2 (ja) 2014-09-17 2017-12-20 トヨタ紡織株式会社 柱状集合体
CN108530617B (zh) * 2017-03-05 2020-11-27 厦门赛诺邦格生物科技股份有限公司 一种支化聚乙二醇异双官能化衍生物、其制备方法及其双组份生物相关物质缀合物

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0239400B1 (en) 1986-03-27 1994-08-03 Medical Research Council Recombinant antibodies and methods for their production
US4956303A (en) 1986-04-28 1990-09-11 Antibody Technology Limited Secondary antibodies against complexes of small molecules and binding partners therefor, their preparation, and their use in diagnostic methods
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0592106B1 (en) 1992-09-09 2004-11-24 Immunogen Inc Resurfacing of rodent antibodies
US20020142358A1 (en) 2000-04-28 2002-10-03 Toshifumi Mikayama Human anti-CD40 antibodies and methods of making and using same
US20030211100A1 (en) 2001-11-09 2003-11-13 Vahe Bedian Antibodies to CD40
US20040006215A1 (en) 2002-01-09 2004-01-08 Tibor Keler Human monoclonal antibodies against CD30
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US8163888B2 (en) 2003-10-10 2012-04-24 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005058367A2 (en) 2003-12-16 2005-06-30 Nektar Therapeutics Al, Corporation Pegylated small molecules
WO2005108463A2 (en) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US20080171040A1 (en) 2004-06-01 2008-07-17 Genentech, Inc. Antibody-drug conjugates and methods
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
WO2011023883A1 (fr) 2009-08-25 2011-03-03 Sanofi-Aventis Conjugues de dimeres de pyrrolo [1, 4 ] benzodiazepine en tant qu' anticancereux
WO2018181059A1 (ja) * 2017-03-30 2018-10-04 日油株式会社 ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体
WO2019176875A1 (ja) * 2018-03-13 2019-09-19 日油株式会社 主鎖および側鎖に単分散ポリエチレングリコールを有するヘテロ二官能性化合物
JP2019176066A (ja) 2018-03-29 2019-10-10 アオイ電子株式会社 半導体装置

Non-Patent Citations (43)

* Cited by examiner, † Cited by third party
Title
"PEGylated Protein Drugs: Basic Science and Clinical Applications", 2009, BIRKHAUSER
ANGEW CHEM INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
AXUP, J.Y. ET AL., PROC NATL ACAD SCI, vol. 109, 2012, pages 16101 - 16106
BIOMATERIALS, vol. 22, no. 5, 2001, pages 405 - 417
BIRD, R. E. ET AL., SCIENCE, vol. 242, 1988, pages 423 - 442
BIRDSALL, R. E. ET AL., MABS, vol. 7, 2015, pages 1036 - 1044
BOWEN, M. A. ET AL., J. IMMUNOL., vol. 151, 1993, pages 5896 - 5906
CEZARI, M.H.S. ET AL., BIOCHEM. J., vol. 368, 2002, pages 365 - 369
CHARI, R.V.J. ET AL., CANCER RES, vol. 52, 1992, pages 127 - 131
CHEN, J. ET AL., ANAL. CHEM., vol. 85, 2013, pages 1699 - 1704
CHENG, T. ET AL., J CHEM INF MODEL, vol. 47, 2007, pages 2140 - 2148
COLE, S. P. C.ALAN R. LISS ET AL., MONOCLONAL ANTIBODIES AND CANCER THERAPY, 1985, pages 77 - 96
DORONINA, S.O. ET AL., NAT BIOTECHNOL, vol. 21, 2003, pages 778 - 784
FRANCISCO, J. A. ET AL., CANCER RES, vol. 60, 2000, pages 3225 - 3231
FRANCISCO, J.A. ET AL., BLOOD, vol. 102, 2003, pages 1458 - 1465
HAMBLETT, K. J. ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 7063 - 7070
HELLSTROM, K. E. ET AL.: "Controlled Drug Delivery", 1987, MARCEL DEKKER, INC., article "Antibodies for drug delivery", pages: 623 - 653
HERMANSON, G. T.: "Bioconjugate Techniques", 2008, ACADEMIC PRESS
HUSTON, J. S. ET AL., PROC. NATL. ACAD. SOT USA, vol. 85, 1988, pages 5879 - 5883
JANEWAY, C.TRAVERS, P.WALPORT, M.SHLOMCHIK, M.: "Immunobiology", 2001, GARLAN PUBLISHING
KOHLER, GMILSTEIN, C, NATURE, vol. 256, 1975, pages 495 - 497
KOZBOR, D. ET AL., IMMUNOL. TODAY, vol. 4, 1983, pages 72 - 79
KOZBOR, D. ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72 - 79
KYTE JDOOLITTLE RF, J MOL BIOL, vol. 157, 1982, pages 105 - 132
MANT, C.T. ET AL., METHODS MOL BIOL, vol. 386, 2007, pages 3 - 55
MILLER, K. ET AL., J. IMMUNOL., vol. 170, 2003, pages 4854 - 4861
MILSTEIN, C ET AL., NATURE, vol. 305, 1983, pages 537 - 539
NATURE BIOTECHNOLOGY, vol. 33, 2015, pages 733 - 735
OLSSON, L. ET AL., METH. ENZYMOL., vol. 92, 1982, pages 3 - 16
ORDER, S.E. ET AL.: "Monoclonal antibodies for cancer detection and therapy", 1985, ACADEMIC PRESS, article "Analysis, results, and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy", pages: 367 - 382
PORTARO, F. C. ET AL., BIOCHEM. J., vol. 347, 2000, pages 123 - 129
See also references of EP4036149A4
TENG, N. N. ET AL., PROC. NATL. ACAD. SCI. USA., vol. 80, 1983, pages 7308 - 7312
THORPE, P. E. ET AL., MONOCLONAL ANTIBODIES, vol. 84, 1985, pages 475 - 506
THORPE, P.E ET AL., IMMUNOL REV, vol. 62, 1982, pages 119 - 158
TIAN, F. ET AL., PROC NATL ACAD SCI, vol. 111, 2014, pages 1766 - 1771
TRAIL, P. A. ET AL., CANCER RESEARCH, vol. 57, 1997, pages 100 - 105
TRAIL, P. A. ET AL., SCIENCE, vol. 261, 1993, pages 212 - 215
TUMEY, L.N., ACS MED. CHEM. LETT., vol. 7, 2016, pages 977 - 982
VALLIERE-DOUGLASS, J. F. ET AL., ANAL. CHEM., vol. 84, 2012, pages 2843 - 2849
WAHL, A. F. ET AL., CANCER RES, vol. 62, no. 13, 2002, pages 3736 - 42
WARD, E. S. ET AL., NATURE, vol. 334, 1989, pages 544 - 554
ZHAO, R. Y. ET AL., J. MED. CHEM., vol. 54, 2011, pages 3606 - 3623

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023095741A1 (ja) * 2021-11-25 2023-06-01 日油株式会社 医療用４分岐型水溶性ポリマー

Also Published As

Publication number Publication date
US20220362397A1 (en) 2022-11-17
EP4036149A1 (en) 2022-08-03
KR20220069989A (ko) 2022-05-27
JPWO2021060439A1 (US08088387-20120103-C00002.png) 2021-04-01
EP4036149A4 (en) 2023-10-25
CN114450324A (zh) 2022-05-06
CA3156027A1 (en) 2021-04-01
CN114450324B (zh) 2024-02-27

Similar Documents

Publication Publication Date Title
WO2020236817A2 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2012153193A2 (en) Protein-active agent conjugates and method for preparing the same
TW202210517A (zh) 抗ｂｃｍａ抗體－藥物軛合物及其使用方法
JP6990355B2 (ja) ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体
WO2021060439A1 (ja) ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール
KR102542988B1 (ko) 주쇄 및 측쇄에 단분산 폴리에틸렌 글리콜을 가지는 헤테로이관능성 화합물
US10808050B2 (en) Antibody-drug conjugate having cyclic benzylidene acetal linker
JP7022328B2 (ja) 自壊性アセタールリンカーを有する親水性ポリマー誘導体及びそれを用いた複合体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20868583

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021549023

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3156027

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20227013431

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020868583

Country of ref document: EP

Effective date: 20220426